Key result
Levosimendan provides inotropic and vasodilatory effects across CV conditions despite mixed long-term mortality evidence.
Why the study?
Levosimendan use has expanded far beyond its initial indications across cardiovascular pathology, prompting a review of its pharmacology and key randomized clinical trials.
Does levosimendan improve clinical outcomes in patients with heart failure, myocardial infarction, cardiogenic shock, and those undergoing cardiac surgery?
Does levosimendan improve clinical outcomes in patients with heart failure, myocardial infarction, cardiogenic shock, and those undergoing cardiac surgery?
This review summarizes the pharmacological properties and clinical evidence for levosimendan across multiple cardiovascular indications, highlighting its role as an inodilator in heart failure and cardiac surgery.
Cautious acute use only in select HF and surgery cases; leaves open long-term mortality benefit for prospective trials.
Levosimendan belongs to the class of calcium sensitizers, which exhibits its positive inotropic effects by increasing the affinity of troponin from the myocardium to calcium without additional myocardial oxygen demand, what favorably distinguishes it from catecholamines and their negative effects (myocardial ischemia, arrhythmias, vasoconstriction, hyperglycemia). In 2000, the drug was first used for the short-term treatment of decompensated chronic heart failure. After more than 20 years, the clinical use of levosimendan has covered a wide area among patients with pathology of the cardiovascular system and its use has gone far beyond the primary indications. To date, the drug has been studied in more than 200 randomized trials in patients with various clinical profiles: acute decompensation of chronic heart failure, progressive heart failure, acute myocardial infarction, cardiogenic shock, therapy of low cardiac output syndrome in cardiac surgery, perioperative use in pediatric cardiac surgery, septic shock, pulmonary hypertension, right ventricular failure, Takotsubo cardiomyopathy, patients with mechanical circulatory support devices. This review highlights the pharmacological features of the drug and key randomized clinical trials on the use of levosimendan in various categories of patients, in addition to officially recommended indications. The article also provides a brief overview of current and planned randomized trials.
No takes yet. Share an insight, caveat, or question.
Boboshko et al. (2023) conducted a review in Heart failure, low cardiac output syndrome, myocardial infarction, cardiogenic shock, sepsis. Levosimendan was evaluated. Levosimendan is a calcium sensitizer that provides positive inotropic and vasodilatory effects across various cardiovascular conditions, though evidence for long-term mortality benefit remains mixed.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: